Glaukos stock holds near yearly highs as insider sale draws attention

Published on 09/19/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos stock trades near its recent 52-week high as of September 17, 2026, after a strong year-to-date gain. An insider sale on September 16, 2026 highlights how far the mid-cap ophthalmic group has rallied.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos Corporation stock (ISIN US3773221029) has delivered a year-to-date performance of 44.78 percent as of September 17, 2026, putting the mid-cap ophthalmic group among the stronger performers in US health care names this year.

Insider sale underscores strong share rally

According to StockTitan, Glaukos reported in a Form 4 filing that its Chief Development Officer Tomas Navratil sold a total of 1,457 shares of common stock on September 16, 2026 under a Rule 10b5-1 trading plan adopted on June 12, 2026.

The filing shows weighted-average sale prices ranging from USD 163.20 to USD 172.00 per share on September 16, 2026, illustrating that the transactions took place at levels close to Glaukos stock’s recent trading range.

Momentum and year-to-date performance

In a healthcare momentum overview published on September 17, 2026, Ad-hoc-news cites Seeking Alpha data that assign Glaukos an A momentum grade and report a year-to-date performance of 44.78 percent for GKOS as of September 17, 2026.

The same overview places Glaukos at USD 161.20 with a daily move of minus 1.39 percent in USD on September 17, 2026, indicating that the stock is trading close to its recent 52-week high range while still showing a solid gain for 2026.

Stock level and market positioning

Per the latest summary of Glaukos stock key data compiled on September 17, 2026 by Ad-hoc-news, GKOS traded at USD 161.20 on its primary listing at the New York Stock Exchange as of September 17, 2026.

The same snapshot puts Glaukos’s market capitalization at approximately USD 5,495,000,000 as of September 17, 2026, underlining its profile as a mid-cap health care company focused on ophthalmic devices and drug therapies.

Closing stock view

With Glaukos stock at USD 161.20 on the New York Stock Exchange as of September 17, 2026, the shares remain near their recent 52-week high range and reflect the strong year-to-date performance of 44.78 percent reported for mid-September 2026.